You have fifteen minutes with the doctor and one question you feel sheepish about asking. This article is for that situation.
More precisely, it is for the person in St. Peters who has read something about ketamine or esketamine for depression, does not buy the hype, and still wants a straight answer from someone qualified to give one. You need not arrive convinced. You need to arrive organized.
Survey evidence says this instinct is the common one. Among 443 adults we polled across ten Midwest states, a cautious but open reaction was the most frequent at 34 percent, and hope or curiosity came from 18 percent. Skeptical and negative reactions came to 21 and 9 percent, while another 18 percent were hearing of the idea for the first time. About half lean open; hard opposition is below one in ten.
The same respondents said where the question belongs: 56 percent would take it to their primary doctor first, and for 74 percent, advice from their own doctor was what would actually move them, against 2 percent for an ad. So the conversation below is not a workaround. It is where nearly everyone says the decision lives.
Before the visit, write down three things
- Each antidepressant so far, about how many months you stayed on it, and why it stopped. Approximate is fine; this list drives most of the answer.
- What you are experiencing now, in your own words, including sleep, appetite, and whether you can work.
- Whatever you saw or heard that sent you looking, including a clinic's name if there was one.
That last item matters more than people expect. Your doctor's answer changes depending on whether you mean a certified esketamine program, an infusion clinic, or a website that mails lozenges.
Opening lines that do not oversell
"I am not asking you to start me on anything. I want to know whether I am even the kind of patient this is for."
"I keep seeing ads for ketamine clinics and I do not trust them. Is there a version of this that is actually approved?"
"Two medications have not worked for me. What is the next step in your thinking, whatever it is?"
The last is the most useful sentence here, because it commits you to nothing. It asks the person with your chart to name the next move. If that is a different antidepressant, an augmentation strategy, a therapy referral, or an evaluation for something else, you got what you came for.
Questions that get precise answers
- "Does my history meet the definition of treatment-resistant depression, or am I not there yet?"
- "Esketamine is the approved one, correct? How is that different from what these clinics advertise?"
- "If you thought this was reasonable for me, who would you send me to?"
- "What would you want me to try before that?"
- "What in my chart would make this a bad idea?"
- "Would you stay involved and manage the rest of my care if I went?"
Ask them in that order. Each narrows the next, and the last keeps your care in one place.
If your doctor does not know much about it
That happens, and it is not a failing. In our survey of the general public, Spravato was unheard of for 73 percent; 21 percent had the name without the meaning, and 6 percent knew what it was. Awareness is thin everywhere, and a busy primary care physician may rarely see it come up.
Do not argue. Ask a smaller question: "Would you refer me to a psychiatrist to answer this?" Our respondents already lean that way, with 23 percent naming a psychiatrist or other mental health clinician as their first stop. A referral turns an uncertain answer into a scheduled one. What you should not do is take silence as a no and buy something online instead; the gray end of this market exists because people leave appointments without answers.
Bring up money in the room
It feels rude. Do it anyway, because coverage predicted more than anything else we measured. Insurance would decide or heavily sway 65 percent of respondents, and 85 percent placed it in their top two provider considerations. Weighing coverage-with-hoops against a quicker self-paid start, 51 percent chose the hoops, while paying (23 percent) and indecision (26 percent) split the rest.
Try: "If you refer me, can you point me somewhere that takes my insurance?" If you are on MO HealthNet, say so plainly. Medicaid was 37 percent of our payer mix, nearly tied with commercial coverage at 39, so this is a mainstream question, not an awkward one. Some people also like to read a clinic's own description beforehand; Brain Recovery Centers has a page describing its Spravato treatment you could print and bring.
After the appointment
Write down what was said while it is fresh, including any medication or program named and any referral. If you were told to try something else first, put a date on the calendar to report back. A follow-up already on the calendar is the difference between a plan and a conversation.
If you leave with a no, ask what would change it. "What would have to be true for this to be on the table for me?" turns a closed door into a condition.
What this is not
This article recommends no treatment and cannot tell you whether one is right for you. It is a set of sentences for a conversation with the person qualified to decide. Esketamine's approval covers depression that other treatment could not lift, and it is only ever dosed under observation in certified offices; other ketamine arrangements carry different oversight, and a public-opinion survey should not be used to judge any of them.
If waiting for an appointment is not realistic because you are thinking about ending your life, that is a different situation with a different number. Call or text 988 for the Lifeline, free and open every hour, and use it before things get worse.
Methodology
The survey data comes from Pollfish study 395586438, a first-party poll this publisher commissioned and funded, which finished fieldwork on June 23, 2026. The 443 people who answered, all 18 to 64 and spread across ten Midwest states, came from an ordinary consumer panel, not a patient registry. On questions permitting several selections, percentages are shares of respondents and sum past 100. Pollfish finished validating the data before we reported it. Only aggregate top-line figures appear, and nothing here describes a subset of respondents.